NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

Author： Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.451, Iss.2, 2002-09, pp. : 217-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

By Saraceni Christine   Broderick Tom L.  

Drugs in R&D, Vol. 8, Iss. 3, 2007-01 ,pp. : 145-153

Adis International

Access to resources Recommend Favorite

Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative

By Agerso H.   Vicini P.  

European Journal of Pharmaceutical Sciences, Vol. 19, Iss. 2, 2003-06 ,pp. : 141-150

Elsevier

Access to resources Recommend Favorite

Cardiovascular Effects of Glucagon-Like Peptide 1

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 1, 2011-01 ,pp. : 97-105

Bentham Science Publishers

Access to resources Recommend Favorite

Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents

By  

Current Pharmaceutical Design, Vol. 10, Iss. 29, 2004-11 ,pp. : 3651-3662

Bentham Science Publishers

Access to resources Recommend Favorite

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

By Retterstøl Kjetil  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1405-1411

Informa Healthcare

Access to resources Recommend Favorite